4d Pharma PLC Exercise of Options and Total Voting Rights (7715Q)
March 01 2021 - 11:49AM
UK Regulatory
TIDMDDDD
RNS Number : 7715Q
4d Pharma PLC
01 March 2021
Exercise of Options and Total Voting Rights
Leeds, UK, March 1, 2021 , - 4D pharma plc (AIM: DDDD), a
pharmaceutical company leading the development of Live
Biotherapeutic products (LBPs) - a novel class of drug derived from
the microbiome, today announces that 67,969 ordinary shares of 0.25
pence each in the capital of the Company ("New Ordinary Shares")
have been issued as a result of the exercise of employee share
options under the Company's approved Long-Term Incentive Plan on 26
February 2021.
Application has been made for the New Ordinary Shares, which
rank pari passu in all respects with the Company's existing
Ordinary Shares, to be admitted to trading on AIM which is expected
to occur on 5 March 2021.
Following the issue of the New Ordinary Shares, the Company's
total issued share capital will consist of 131,566,524 Ordinary
Shares with one voting right per share. The Company does not hold
any Ordinary Shares in Treasury. Therefore, following the issue of
the New Ordinary Shares, the total number of voting rights in the
Company will be 131,566,524. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
About 4D pharma
Founded in February 2014, 4D pharma is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform, MicroRx(R), that rationally identifies Live
Biotherapeutics based on a deep understanding of function and
mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma (NCT03851250), a Phase II study of
MRx-4DP0004 in patients hospitalized with COVID-19 (NCT04363372),
and Blautix(R) in Irritable Bowel Syndrome (IBS) (NCT03721107)
which has completed a successful Phase II trial. Preclinical-stage
programs include candidates for CNS disease such as Parkinson's
disease and other neurodegenerative conditions. The Company has a
research collaboration with MSD, a tradename of Merck & Co.,
Inc., Kenilworth, NJ, USA, to discover and develop Live
Biotherapeutics for vaccines.
In October 2020 4D pharma announced its intention to merge with
Longevity Acquisition Corporation (NASDAQ: LOAC), a special purpose
acquisition company (SPAC), and seek a NASDAQ listing. The merger
is expected to be completed and the NASDAQ listing of 4D pharma
American Depositary Shares (ADSs) under the ticker symbol 'LBPS' is
currently expected to become effective in early 2021, subject to
the satisfaction of closing conditions, including approval of 4D
shareholders and Longevity shareholders and the approval by Nasdaq
of the listing of ADSs.
For more information, refer to www.4dpharmaplc.com .
Contact Information:
4D pharma
Investor Relations: ir@4dpharmaplc.com
Stern Investor Relations, Inc.
Julie Seidel
+1-212-362-1200
Julie.seidel@sternir.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496
3000
Philip Davies / Iqra Amin / James Fischer (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500
Dominic Wilson / Phil Walker
Image Box Communications
Neil Hunter / Michelle Boxall +44 (0)20 8943 4685
neil@ibcomms.agency / michelle@ibcomms.agency
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEBRGDXRSGDGBB
(END) Dow Jones Newswires
March 01, 2021 12:49 ET (17:49 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024